Recombinant Anti-ErbB2 / HER2 (phospho Y877) antibody [EP2324Y] (ab108371)
![Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-ErbB2 / HER2 (phospho Y877) antibody [EP2324Y] (ab108371)](https://www.abcam.com/ps/products/108/ab108371/Images/ab108371-121009-anti-erbb-2-phospho-y877-antibody-ep2324y-immunohistochemistry.jpg "Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-ErbB2 / HER2 (phospho Y877) antibody [EP2324Y] (ab108371)")
Key features and details
- Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
- Rabbit monoclonal [EP2324Y] to ErbB2 / HER2 (phospho Y877)
- Suitable for: WB, IHC-P, Dot blot, ICC/IF, Flow Cyt (Intra)
- Reacts with: Human
Related conjugates and formulations
Overview
-
Product name
Anti-ErbB2 / HER2 (phospho Y877) antibody [EP2324Y]
See all ErbB2 / HER2 primary antibodies -
Description
Rabbit monoclonal [EP2324Y] to ErbB2 / HER2 (phospho Y877) -
Host species
Rabbit -
Tested applications
Suitable for: WB, IHC-P, Dot blot, ICC/IF, Flow Cyt (Intra)more details
Unsuitable for: IP -
Species reactivity
Reacts with: Human -
Immunogen
Synthetic peptide. This information is proprietary to Abcam and/or its suppliers.
-
Positive control
- HeLa cell lysate, SKBR-3 cell lysate, Human breast ductal infiltrating carcinoma tissue, SKBR-3 cells.
-
General notes
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free production
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
We are constantly working hard to ensure we provide our customers with best in class antibodies. As a result of this work we are pleased to now offer this antibody in purified format. We are in the process of updating our datasheets. The purified format is designated 'PUR' on our product labels. If you have any questions regarding this update, please contact our Scientific Support team.
Mouse, Rat: We have preliminary internal testing data to indicate this antibody may not react with these species. Please contact us for more information.
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Store at -20°C. Stable for 12 months at -20°C. -
Storage buffer
pH: 7.20
Preservative: 0.01% Sodium azide
Constituents: 0.31% Sodium citrate, 0.175% Sodium chloride, 0.0172% EDTA disodium salt, 59% PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA -
Concentration information loading... -
Purity
Protein A purified -
Clonality
Monoclonal -
Clone number
EP2324Y -
Isotype
IgG -
Research areas
Associated products
-
Alternative Versions
-
Isotype control
-
Positive Controls
-
Recombinant Protein
Applications
The Abpromise guarantee
Our Abpromise guarantee covers the use of ab108371 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
| Application | Abreviews | Notes |
|---|---|---|
| WB | (1) |
1/500 - 1/1000. Predicted molecular weight: 138 kDa.
|
| IHC-P |
1/250 - 1/500. Perform heat mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol.
Perform antigen retrieval before commencing with IHC staining protocol |
|
| Dot blot |
1/1000.
|
|
| ICC/IF |
1/50 - 1/100.
|
|
| Flow Cyt (Intra) |
Use at an assay dependent concentration.
|
| Notes |
|---|
|
WB
1/500 - 1/1000. Predicted molecular weight: 138 kDa. |
|
IHC-P
1/250 - 1/500. Perform heat mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol. Perform antigen retrieval before commencing with IHC staining protocol |
|
Dot blot
1/1000. |
|
ICC/IF
1/50 - 1/100. |
|
Flow Cyt (Intra)
Use at an assay dependent concentration. |
Target
-
Function
Protein tyrosine kinase that is part of several cell surface receptor complexes, but that apparently needs a coreceptor for ligand binding. Essential component of a neuregulin-receptor complex, although neuregulins do not interact with it alone. GP30 is a potential ligand for this receptor. Regulates outgrowth and stabilization of peripheral microtubules (MTs). Upon ERBB2 activation, the MEMO1-RHOA-DIAPH1 signaling pathway elicits the phosphorylation and thus the inhibition of GSK3B at cell membrane. This prevents the phosphorylation of APC and CLASP2, allowing its association with the cell membrane. In turn, membrane-bound APC allows the localization of MACF1 to the cell membrane, which is required for microtubule capture and stabilization.
In the nucleus is involved in transcriptional regulation. Associates with the 5'-TCAAATTC-3' sequence in the PTGS2/COX-2 promoter and activates its transcription. Implicated in transcriptional activation of CDKN1A; the function involves STAT3 and SRC. Involved in the transcription of rRNA genes by RNA Pol I and enhances protein synthesis and cell growth. -
Tissue specificity
Expressed in a variety of tumor tissues including primary breast tumors and tumors from small bowel, esophagus, kidney and mouth. -
Involvement in disease
Hereditary diffuse gastric cancer
Glioma
Ovarian cancer
Lung cancer
Gastric cancer
Chromosomal aberrations involving ERBB2 may be a cause gastric cancer. Deletions within 17q12 region producing fusion transcripts with CDK12, leading to CDK12-ERBB2 fusion leading to truncated CDK12 protein not in-frame with ERBB2. -
Sequence similarities
Belongs to the protein kinase superfamily. Tyr protein kinase family. EGF receptor subfamily.
Contains 1 protein kinase domain. -
Post-translational
modificationsAutophosphorylated. Autophosphorylation occurs in trans, i.e. one subunit of the dimeric receptor phosphorylates tyrosine residues on the other subunit (Probable). Ligand-binding increases phosphorylation on tyrosine residues (PubMed:27134172). Signaling via SEMA4C promotes phosphorylation at Tyr-1248 (PubMed:17554007). Dephosphorylated by PTPN12 (PubMed:27134172). -
Cellular localization
Cytoplasm. Nucleus and Cell membrane. Cytoplasm, perinuclear region. Nucleus. Translocation to the nucleus requires endocytosis, probably endosomal sorting and is mediated by importin beta-1/KPNB1. - Information by UniProt
-
Database links
- Entrez Gene: 2064 Human
- Omim: 164870 Human
- SwissProt: P04626 Human
- Unigene: 446352 Human
-
Alternative names
- Verb b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived oncogene homolog antibody
- C erb B2/neu protein antibody
- CD340 antibody
see all
Images
-
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-ErbB2 / HER2 (phospho Y877) antibody [EP2324Y] (ab108371)
ab108371, at 1/250, staining Human ErbB2 / HER2 (phospho Y877) in Human breast ductal infiltrating carcinoma tissue by immunohistochemistry.
Perform heat mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol.
-
![Western blot - Anti-ErbB2 / HER2 (phospho Y877) antibody [EP2324Y] (ab108371)](https://www.abcam.com/ps/products/108/ab108371/Images/ab108371-255424-anti-erbb-2-phospho-y877-antibody-ep2324y-western-blot.jpg)
Western blot - Anti-ErbB2 / HER2 (phospho Y877) antibody [EP2324Y] (ab108371)All lanes : Anti-ErbB2 / HER2 (phospho Y877) antibody [EP2324Y] (ab108371) at 1/1000 dilution
Lane 1 : A431 cell lysate - untreated
Lane 2 : A431 cell lysate - treated with Epidermal Growth Factor (EGF)
Lysates/proteins at 10 µg per lane.
Secondary
All lanes : Peroxidase-conjugated goat anti-rabbit IgG (H+L) at 1/100000 dilution
Predicted band size: 138 kDa
Observed band size: 180 kDa why is the actual band size different from the predicted?
Exposure time: 1 minuteBlocking and dilution buffer: 5% NFDM/TBST.
-
![Flow Cytometry (Intracellular) - Anti-ErbB2 / HER2 (phospho Y877) antibody [EP2324Y] (ab108371)](https://www.abcam.com/ps/products/108/ab108371/Images/ab108371-276593-anti-erbb-2-phospho-y877-antibody-ep2324y-flow-cytometry.jpg)
Flow Cytometry (Intracellular) - Anti-ErbB2 / HER2 (phospho Y877) antibody [EP2324Y] (ab108371)Intracellular Flow Cytometry analysis of A431 (human epidermoid carcinoma) untreated/treated with 200 ng/ml EGF for 15 minutes labeling ErbB2 / HER2 with purified ab108371 at 1/20. Cells were fixed with 4% paraformaldehyde and permeabilised with 90% methanol. A Goat Anti-Rabbit IgG H&L (Alexa Fluor® 488) (ab150077) (1/2000 dilution) was used as the secondary antibody. Rabbit IgG, monoclonal [EPR25A] - Isotype Control (ab172730) (Black) was used as the isotype control, cells without incubation with primary antibody and secondary antibody (Blue) were used as the unlabeled control.
-
![Dot Blot - Anti-ErbB2 / HER2 (phospho Y877) antibody [EP2324Y] (ab108371)](https://www.abcam.com/ps/products/108/ab108371/Images/ab108371-255423-anti-erbb-2-phospho-y877-antibody-ep2324y-dot-blot.jpg)
Dot Blot - Anti-ErbB2 / HER2 (phospho Y877) antibody [EP2324Y] (ab108371)Dot blot analysis of ErbB 2 (pY877) peptide (Lane 1) and ErbB2 / HER2 non-phospho peptide (Lane 2) labelling ErbB 2 (phospho Y877) with ab108371 at a dilution of 1/1000. A Peroxidase-conjugated goat anti-rabbit IgG (H+L) was used as the secondary antibody at a dilution of 1/2500.
Blocking and dilution buffer: 5% NFDM/TBST.
Exposure time: 3 minutes.
-
![Western blot - Anti-ErbB2 / HER2 (phospho Y877) antibody [EP2324Y] (ab108371)](https://www.abcam.com/ps/products/108/ab108371/Images/ab108371-121010-anti-erbb-2-phospho-y877-antibody-ep2324y-western-blot.jpg)
Western blot - Anti-ErbB2 / HER2 (phospho Y877) antibody [EP2324Y] (ab108371)All lanes : Anti-ErbB2 / HER2 (phospho Y877) antibody [EP2324Y] (ab108371) at 1/500 dilution
Lane 1 : HeLa cell lysate
Lane 2 : EGF treated HeLa cell lysate
Lane 3 : SKBR-3 cell lysate
Lane 4 : EGF treated SKBR-3 cell lysate
Lysates/proteins at 10 µg per lane.
Predicted band size: 138 kDa -
![Immunocytochemistry/ Immunofluorescence - Anti-ErbB2 / HER2 (phospho Y877) antibody [EP2324Y] (ab108371)](https://www.abcam.com/ps/products/108/ab108371/Images/ab108371-121008-anti-erbb-2-phospho-y877-antibody-ep2324y-immunofluorescence.jpg)
Immunocytochemistry/ Immunofluorescence - Anti-ErbB2 / HER2 (phospho Y877) antibody [EP2324Y] (ab108371)ab108371, at 1/50 dilution, staining Human ErbB2 / HER2 (phospho Y877) in SKBR-3 cells by immunofluorescence.
-
![Anti-ErbB2 / HER2 (phospho Y877) antibody [EP2324Y] (ab108371)](https://www.abcam.com/ps/products/108/ab108371/Images/ab108371-7-benefits-of-recombinant-antibodies.png)
Anti-ErbB2 / HER2 (phospho Y877) antibody [EP2324Y] (ab108371)
Protocols
Datasheets and documents
-
SDS download
-
Datasheet download
References (8)
ab108371 has been referenced in 8 publications.
- Li L et al. Neuregulin-1 promotes the proliferation, migration, and angiogenesis of human periodontal ligament stem cells in vitro. Cell Biol Int 46:792-805 (2022). PubMed: 35077607
- Yeo MK et al. HER2 Expression in Peritoneal Dissemination of High-Grade Serous Ovarian Carcinoma: A Comparative Study of Immunohistochemical Reactivity Using Four HER2 Antibodies. J Clin Med 11:N/A (2022). PubMed: 36498537
- Burguin A et al. Trastuzumab effects depend on HER2 phosphorylation in HER2-negative breast cancer cell lines. PLoS One 15:e0234991 (2020). PubMed: 32584853
- Oh DY et al. Precision medicine approaches to lung adenocarcinoma with concomitant MET and HER2 amplification. BMC Cancer 17:535 (2017). PubMed: 28806950
- Mo T et al. Effect of Fu-Zheng-Xiao-Liu Granules on Expression of Human Epidermal Growth Factor Receptor 2 (HER-2) and Proliferation and Apoptosis of Breast Cancer Cell Line SKBR-3. Med Sci Monit 22:5068-5073 (2016). PubMed: 28008166
- Shekhar A et al. Transcription factor ETV1 is essential for rapid conduction in the heart. J Clin Invest 126:4444-4459 (2016). IHC-Fr ; Mouse . PubMed: 27775552
- Sanabria-Figueroa E et al. Insulin-like growth factor-1 receptor signaling increases the invasive potential of human epidermal growth factor receptor 2-overexpressing breast cancer cells via Src-focal adhesion kinase and forkhead box protein M1. Mol Pharmacol 87:150-61 (2015). PubMed: 25391374
- Oh DY et al. HER2 as a novel therapeutic target for cervical cancer. Oncotarget 6:36219-30 (2015). WB . PubMed: 26435481